NHS ‘nowhere near ready’ to deliver new Alzheimer’s drug, doctors say

Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructure

A reorganisation of NHS dementia care is needed to ensure UK patients can receive a groundbreaking drug that slows the progression of Alzheimer’s disease, doctors say.

Detailed results from a clinical trial of lecanemab have confirmed that the drug reduces cognitive decline in patients with early-stage Alzheimer’s, in a hard-won breakthrough hailed as a historic moment for the field.

Continue reading…

​Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructureA reorganisation of NHS dementia care is needed to ensure UK patients can receive a groundbreaking drug that slows the progression of Alzheimer’s disease, doctors say.Detailed results from a clinical trial of lecanemab have confirmed that the drug reduces cognitive decline in patients with early-stage Alzheimer’s, in a hard-won breakthrough hailed as a historic moment for the field. Continue reading…